Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
HIV Clinical Trials
|
August 2, 2012
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK
Edwin DeJesus, Jürgen K Rockstroh, Jeffrey L Lennox, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 28, 2007
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study
Martin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 4, 2009
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection
Martin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Journal of the Pediatric Infectious Diseases Society
|
October 10, 2023
Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014
Supattra Rungmaitree, Linda Aurpibul, Brookie M Best, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 16, 2009
Effects of omeprazole on plasma levels of raltegravir
Marian Iwamoto, Larissa A Wenning, Bach-Yen Nguyen, et al.
Antiviral Therapy
|
July 30, 2019
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial
Jose M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 21, 2010
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses
Jeffrey L Lennox, Edwin Dejesus, Daniel S Berger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 10, 2022
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014
Ann J Melvin, Ka Lai Yee, Kathryn P Gray, et al.
Annals of the New York Academy of Sciences
|
March 26, 2011
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium
Bach-Yen T Nguyen, Robin D Isaacs, Hedy Teppler, et al.
The Lancet. Infectious Diseases
|
May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
Joseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
HIV Clinical Trials
|
August 2, 2012
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK
Edwin DeJesus, Jürgen K Rockstroh, Jeffrey L Lennox, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 28, 2007
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study
Martin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 4, 2009
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection
Martin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Journal of the Pediatric Infectious Diseases Society
|
October 10, 2023
Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014
Supattra Rungmaitree, Linda Aurpibul, Brookie M Best, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 16, 2009
Effects of omeprazole on plasma levels of raltegravir
Marian Iwamoto, Larissa A Wenning, Bach-Yen Nguyen, et al.
Antiviral Therapy
|
July 30, 2019
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial
Jose M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 21, 2010
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses
Jeffrey L Lennox, Edwin Dejesus, Daniel S Berger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 10, 2022
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014
Ann J Melvin, Ka Lai Yee, Kathryn P Gray, et al.
Annals of the New York Academy of Sciences
|
March 26, 2011
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium
Bach-Yen T Nguyen, Robin D Isaacs, Hedy Teppler, et al.
The Lancet. Infectious Diseases
|
May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
Joseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Page
of 7